Conference item
Use of oral bisphosphonates and bone mineral density changes in moderate-severe (Stage 3B+) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark
- Abstract:
- In addition to safety concerns, there is a paucity of data for oral bisphosphonates (oBP) to improve bone mineral density (BMD) in patients with moderate or severe chronic kidney disease (CKD). We linked all BMD measurements in the Funen area (pop 478,000, Denmark) to biochemistry, national health registries, and filled prescriptions to study the association between oBP use and BMD changes.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 263.7KB, Terms of use)
-
- Publisher copy:
- 10.1002/jbmr.3363
Authors
- Publisher:
- Wiley
- Host title:
- 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR 2017)
- Journal:
- 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR 2017). More from this journal
- Publication date:
- 2017-12-28
- Acceptance date:
- 2017-06-29
- DOI:
- Pubs id:
-
pubs:724572
- UUID:
-
uuid:dceb819d-13fa-42a5-80cb-d4c79a885669
- Local pid:
-
pubs:724572
- Source identifiers:
-
724572
- Deposit date:
-
2017-08-30
- ARK identifier:
Terms of use
- Copyright holder:
- American Society for Bone and Mineral Research
- Copyright date:
- 2017
- Notes:
- © 2017 American Society for Bone and Mineral Research. This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1002/jbmr.3363
If you are the owner of this record, you can report an update to it here: Report update to this record